Allergy · AntihistamineRegulatory Approvalcommercialnear-term

FDA Grants Approval for Diphenhydramine Hydrochloride ANDA219470

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Annora Pharma2 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/24/2026, 12:30:35 AM

Assessment confidence: 66% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of a generic version of Diphenhydramine Hydrochloride by Annora Pharma introduces a new competitor in the antihistamine market. This could disrupt pricing and market share for established brands, necessitating strategic adjustments. Regulatory context from FDA (FDA AP — DIPHENHYDRAMINE HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 19 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this new entrant on market share and pricing strategies for existing antihistamine products. The strongest clinical anchor is A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Aut (ClinicalTrials.gov), moderate corpus alignment. In Allergy · Antihistamine, 8 regulatory and 2 competitive items passed relevance filtering for Annora Pharma.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Grants Approval for Tofacitinib Citrate ANDA218900 by Saptalis Pharmaceuticals. This approval allows Annora Pharma to enter the market with a generic antihistamine, potentially increasing competition against established brands.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DIPHENHYDRAMINE HYDROCHLORIDE (ORIG) (FDA). Entity match (annora pharma); Regulatory pathway relevance (nda). The approval indicates compliance with FDA standards, but does not suggest any immediate regulatory changes for existing products.

Key Opportunities

The entry of Annora Pharma's generic product may lead to price competition, impacting revenue for existing antihistamine products and altering market dynamics.
Portfolio teams should assess the impact of this new entrant on market share and pricing strategies for existing antihistamine products.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and pricing strategies from Annora Pharma and competitors.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DIPHENHYDRAMINE HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (annora pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MEPERIDINE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Aut
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Connors Protocol for the Management and Use of Stored Human Specimens (Stored Human Specimens)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Grants Approval for Tofacitinib Citrate ANDA218900 by Saptalis Pharmaceuticals
Humanexa Signalsmedium relevance
Moderate corpus alignment

Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
ULK1's role in cancer progression and its emerging therapeutic potential.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Annora Pharma
Diphenhydramine Hydrochloride

Commercial impact

medium

The entry of Annora Pharma's generic product may lead to price competition, impacting revenue for existing antihistamine products and altering market dynamics.

Regulatory impact

low

The approval indicates compliance with FDA standards, but does not suggest any immediate regulatory changes for existing products.

What to watch

Monitor market entry timelines and pricing strategies from Annora Pharma and competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.